Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
- 1 November 2017
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 86, 5-14
- https://doi.org/10.1016/j.ejca.2017.08.029
Abstract
No abstract availableFunding Information
- Ministry of Healthy of Belgium (KPC-29-054)
- Vriendtjes tegen Kanker (EVO-FOVTK1-O2010)
- The Flemish League against Cancer (EVO-ZKD0344)
- Flanders Innovation & Entrepreneurship (AIO 155009)
This publication has 61 references indexed in Scilit:
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- The patterns and dynamics of genomic instability in metastatic pancreatic cancerNature, 2010
- Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian CarcinomasClinical Cancer Research, 2009
- PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathwaysNucleic Acids Research, 2006